Wells Fargo
DERM icon

Wells Fargo’s Journey Medical DERM Stock Holding History

Wells Fargo’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.2K Sell
7,501
-8,247
-52% -$64K ﹤0.01% 5569
2025
Q4 		$121K Buy
15,748
+8,215
+109% +$64.4K ﹤0.01% 5310
2025
Q3 		$53.6K Buy
7,533
+1,260
+20% +$9.14K ﹤0.01% 5531
2025
Q2 		$45K Buy
+6,273
New +$43.4K ﹤0.01% 5544
2024
Q2 		– Sell
-61
Closed -$224 – 7027
2024
Q1 		$224 Buy
61
+1
+2% +$4 ﹤0.01% 6468
2023
Q4 		$346 Buy
60
+4
+7% +$18 ﹤0.01% 6467
2023
Q3 		$153 Buy
56
+8
+17% +$18 ﹤0.01% 6645
2023
Q2 		$76 Buy
48
+2
+4% +$3 ﹤0.01% 6937
2023
Q1 		$72 Buy
46
+2
+5% +$4 ﹤0.01% 7014
2022
Q4 		$84 Buy
44
+1
+2% +$2 ﹤0.01% 6838
2022
Q3 		$0 Buy
43
+14
+48% +$48 ﹤0.01% 6766
2022
Q2 		$0 Buy
29
+4
+16% +$16 ﹤0.01% 6909
2022
Q1 		$0 Buy
+25
New +$125 ﹤0.01% 7178

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wells Fargo's DERM Position: Q1 2026 in Review

Wells Fargo reduced its Journey Medical (DERM) stake by 52% in Q1 2026, selling an estimated $64K and leaving 7,501 shares worth $35.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5569.

Wells Fargo first reported a position in DERM in Q1 2022 and has held it in 13 quarters since. The position peaked at $121K in Q4 2025. 71 funds tracked by Wall St. Rank hold DERM as of Q1 2026.

  • Wells Fargo held 7,501 shares of Journey Medical worth $35.2K as of Q1 2026.
  • Wells Fargo sold 8,247 Journey Medical shares in Q1 2026, an estimated $64K.
  • Journey Medical made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5569 holding.
  • Wells Fargo first reported a position in Journey Medical in Q1 2022 and has held it in 13 quarters since.
  • Wells Fargo's Journey Medical position peaked at $121K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.